Veracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Cwm LLC

Cwm LLC lifted its position in Veracyte, Inc. (NASDAQ:VCYT) by 215.0% during the third quarter, Holdings Channel reports. The institutional investor owned 4,776 shares of the biotechnology company’s stock after buying an additional 3,260 shares during the quarter. Cwm LLC’s holdings in Veracyte were worth $163,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Inspire Investing LLC raised its position in Veracyte by 2.1% in the second quarter. Inspire Investing LLC now owns 16,462 shares of the biotechnology company’s stock worth $357,000 after acquiring an additional 340 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in shares of Veracyte by 6.9% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 8,198 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 530 shares in the last quarter. Arizona State Retirement System lifted its stake in Veracyte by 3.7% during the second quarter. Arizona State Retirement System now owns 20,806 shares of the biotechnology company’s stock valued at $451,000 after purchasing an additional 733 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Veracyte by 9.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 9,325 shares of the biotechnology company’s stock worth $207,000 after buying an additional 778 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Veracyte by 5.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,823 shares of the biotechnology company’s stock worth $473,000 after buying an additional 1,173 shares during the last quarter.

Insider Transactions at Veracyte

In related news, Director Evan/ Fa Jones sold 5,173 shares of Veracyte stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $35.23, for a total transaction of $182,244.79. Following the completion of the sale, the director now owns 34,343 shares of the company’s stock, valued at approximately $1,209,903.89. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider John Leite sold 5,479 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $29.78, for a total value of $163,164.62. Following the transaction, the insider now owns 76,174 shares in the company, valued at approximately $2,268,461.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Evan/ Fa Jones sold 5,173 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $35.23, for a total transaction of $182,244.79. Following the transaction, the director now directly owns 34,343 shares in the company, valued at approximately $1,209,903.89. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 37,141 shares of company stock valued at $1,180,116. 1.30% of the stock is owned by insiders.

Analysts Set New Price Targets

VCYT has been the subject of a number of recent research reports. Needham & Company LLC increased their price objective on Veracyte from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Guggenheim began coverage on Veracyte in a report on Thursday, October 10th. They set a “buy” rating and a $40.00 target price for the company. Morgan Stanley lifted their price target on Veracyte from $21.00 to $26.00 and gave the stock an “underweight” rating in a research note on Monday, August 12th. Leerink Partners upped their price objective on shares of Veracyte from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, UBS Group initiated coverage on shares of Veracyte in a research report on Wednesday, October 16th. They issued a “buy” rating and a $43.00 target price on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Veracyte presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.67.

Veracyte Price Performance

NASDAQ:VCYT opened at $32.45 on Thursday. The stock has a market cap of $2.48 billion, a PE ratio of -34.52 and a beta of 1.67. Veracyte, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $35.51. The stock’s 50-day moving average is $32.57 and its two-hundred day moving average is $25.77.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.10. Veracyte had a negative net margin of 13.52% and a positive return on equity of 1.52%. The firm had revenue of $114.43 million for the quarter, compared to the consensus estimate of $100.27 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The firm’s revenue was up 26.7% on a year-over-year basis. On average, equities research analysts anticipate that Veracyte, Inc. will post 0.16 earnings per share for the current year.

About Veracyte

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.